Objectives: Gout, a chronic inflammatory arthritis, can result in extensive medical problems due to painful flares and joint damage resulting from the build-up of tophi (deposits of uric acid crystals). The prevalence of gout is rising, which is likely to increase the burden of the disease. We determined the current cost impacts of gout and identified key disease burden factors. We also aimed to highlight data gaps for further investigation. MethOds: A systematic literature review was conducted using the MEDLINE database and The Cochrane Library. Articles published in English between January 2000 and July 2014 that reported the economic burden (in terms of either direct or indirect costs) were identified, and patient and cost data were collated, with key themes and data gaps identified. Results: Of the 323 studies identified, 13 primary studies were relevant to the economic burden of gout. Key variables included serum uric acid levels, presence of tophi and number of flares, which resulted in high healthcare resource use that was frequently attributed to hospitalisation and inpatient stay. The incremental direct cost of gout was reported to be up to US$21,467 per annum, in cases where patients were experiencing regular acute flares with the presence of tophi. cOnclusiOns: Patient-level costs associated with the treatment and clinical management of gout can be substantial, depending on disease severity. The identified studies were dominated by direct cost analyses; only three studies specifically considered indirect costs. There was a paucity of non-US data, and there was a lack of published studies estimating the population-wide cost. Despite the limited published data, the review identified a growing number of publications in this area in the last 5 years, suggesting healthcare decision makers' increasing awareness of the wider impacts of gout.
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ReliABility of MAnufActuReRS' BudGet iMPAct eStiMAteS foR SeveRe RheuMAtoid ARthRitiS dRuGS in PolAnd
Zawodnik S 1 , Tatara T 1 , Iwanczuk T 1 , Sliwczynski A 2 , Brzozowska M 2 1 Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland, 2 Medical University of Lodz, Lodz, Poland Objectives: To compare the total value of payer's expenditures on Cimzia (certolizumab pegol) and RoActemra (tocilizumab) in patients with severe rheumatoid arthritis estimated in the manufacturers' Budget Impact Analyses (BIAs) submitted with the reimbursement applications to AOTMiT and actual expenditures of the National Health Fund (NHF). MethOds: Annual public payer's expenditures estimated in manufacturers' BIAs for Cimzia and RoActemra and actual expenditures reported by the NHF were compared. RSSs were not taken into account. Analysed drugs were chosen on the basis of the same indication and financing through the same therapeutic programme in Poland. Actual expenditures and population size were taken from the financial reports of the NHF for the first and second year (actual data on 11 months for expenditures were extrapolated to one year) of reimbursement for each drug. Results: For drugs Cimzia and RoActemra in patients with severe rheumatoid arthritis, the sum of total expenditures estimated in BIAs submitted with the reimbursement applications was 18,04 million PLN in the first year and 28,47 million PLN in the second year, and they were lower than the actual expenditures reported by the NHF: 20,03 million PLN and 36,51 million PLN, respectively. The expenditures estimated in BIAs were underestimated by 10% in the first year of reimbursement and 22% in the second year of reimbursement. Population size estimated in BIAs in comparison to its actual size from the NHF reports was underestimated by 61% in the first year and 57% in the second year of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, total payer's expenditures estimated in BIAs submitted with the reimbursement applications were underestimated in comparison to the real life expenditures of the NHF in Poland.
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PRevention of fRAGility fRActuReS in oSteoPoRotic PAtientS: cAn the SecondARy theRAPy helP contAin coStS foR AdMiSSionS? A RetRoSPective, oBSeRvAtionAl cASe contRol Study BASed on ASl PAviA'S AdMiniStRAtive dAtABASeS
Ronco GL 1 , Mirosa D 2 , Silvia V 2 , Carlo C 2 1 Emmonos S. A., Fenegro', Italy, 2 A.S.L. Pavia, Pavia, Italy Objectives: Osteoporosis is one of the commonest bone diseases in which bone fragility is increased. There are several possibilities for the prevention of primary, secondary and tertiary osteoporosis but until now they have not been promoted enough and bone fragility is thought about only after the onset of a fracture (tertiary prevention). Preventative strategies against osteoporosis can be aimed at either optimizing the peak bone mass obtained, or reducing the rate of bone loss. Optimization of peak bone mass may be more amenable to public health strategies. MethOds: A group of patients over 50 year old that has been treated with medicines included in the AIFA Note 79 during a period of 5 years is studied in comparison with a similar group that has not been treated with medicines included in the AIFA Note 79 for the same period time. For both groups are also extracted inpatient and outpatient medical records and medicine prescriptions. Only patients treated for at least three years are considered significant. To avoid confounding the resulting data were standardized and stratified. Results: The total expenditure for patients compliant with therapy who have had access to the hospital is less than twenty-eight percent compared to the total expenditure for patients not receiving therapy or not compliant. cOnclusiOns: Osteoporosis is undersupplied, even though they have a higher charlson-comorbidity index. Still, this study may not clarify whether this is due to costs or patient and physician preference.
PMS123 GendeR diffeRenceS in MedicAtion tAkinG BehAviouR: A cASe of oSteoPoRoSiS
Valentina Orlando V 1 , Francesca Guerriero F 1 , valeria Marina Monetti V 2 , Denise Fiorentino D 1 , Francesca Gimigliano F 3 , Giovanni Iolascon G 3 , Enrica Menditto E 1 1 University of Naples Federico II, Naples, Italy, 2 AORN Cardarelli, Naples, Italy, 3 Second University of Naples, Naples, Italy
Objectives: The aim of this study is to perform gender specific analysis regarding the persistence to antiosteoporotic drugs by using administrative databases. MethOds: The data used for this study were obtained from outpatient drug prescriptions, hospital discharges and ambulatory care records collected from January 1, 2005 to December 31, 2008. The study was designed as a retrospective study cohort. Patients 60 years of age or older were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2006 and December 31, 2006. Persistence was defined as the length of time in days from the date of the index prescription to the date of discontinuation therapy. Discontinuation was evaluated by using the gap method. Results: The final cohort consisted of a total of 7,867 patients (87.2% women). The mean patient age for both genders at the index date was 74.5 years. About one-fifth of all subjects had experienced with spot therapy, but men were more likely than women to have a spot therapy experience (45.4% vs. 14.5%). Approximately 6% of all included patients were switchers: Switching rates were highest for males (18.9%) and lower for female (4.4%). The crude analysis of long-term gender persistence showed a significant difference between women and men users: the relative number of persistence patients after 1 year was 66.4% in men and 44.7% in women. The Kaplan Meier plots of time to persistence start to differ for men vs women approximately 60 days after treatment start. cOnclusiOns: Gender differences in medication taking behaviour is a relevant issue in drug utilization studies. Our analysis showed that women are more likely to be non-persistent than men in osteoporosis ttherapy. Objectives: The aim of our study is to determine the number of osteoporosis patients with pathological fractures by gender in outpatient care based on physiotherapy activities. MethOds: The data come from the financial data base of the National Health Insurance Fund Administration (in Hungarian: OEP) involving the year of 2013. The activity list was provided by the rulebook on the application of the activity code list in out-patient care. The osteoporosis with pathological fractures is listed in the International Classification of Diseases (ICD) with code of M80. Population distribution was taken into account on the basis of the data of the Central Statistical Office from January 1st 2013. Results: Based on 151 physiotherapy activities, the annual patient numbers accounted for 39725 persons in the total population. The patient numbers accounted for 2544 persons for males and 37181 persons for females (10,000 per capita the patient numbers were 40 persons for the total population, 5 persons for males and 72 for females). cOnclusiOns: The higher patient numbers for females can be clearly associated with the prevalence of the basic disease. The total value for the patient numbers by months is higher caused by the aftercare of the same patients that still lasts in the following month. The authors suggest structuring the health care system and distributing resources to follow the needs supported by our findings. Objectives: The aim of our study is to determine the number of osteoporosis patients with pathological fractures by months in outpatient care based on physiotherapy activities. MethOds: The data come from the financial data base of the National Health Insurance Fund Administration (in Hungarian: OEP) covering the year of 2013. The activity list was provided by the rulebook on the application of the activity code list in out-patient care. The osteoporosis with pathological fractures is listed in the International Classification of Diseases (ICD) with code of M80. Results: Based on 151 physiotherapy activities, the annual patient numbers accounted for 85142 persons in the total population by months. The patient numbers accounted for 5063 persons for males and 80079 persons for females. The patient numbers were 86 persons for the total population, 11 persons for males and 154 for females per 10,000 capita. The patient numbers above average by months could be found in the spring and autumn months (average: population= 7095, males= 421, females= 6673). cOnclusiOns: The higher patient numbers for females can be clearly associated with the prevalence of the basic (osteoporosis) disease. It would be interesting to examine the correla-procured, provides alternatives to adjust the budget available and release financial resources for cost effective and sustainable interventions .
PMS124 nuMBeR of oSteoPoRoSiS PAtientS with PAtholoGicAl fRActuReS By GendeR in outPAtient cARe in the liGht of PhySiotheRAPy cARe in hunGARy
PMS125 nuMBeR of oSteoPoRoSiS PAtientS with PAtholoGicAl fRActuReS By MonthS in outPAtient cARe in the liGht of PhySiotheRAPy cARe in hunGARy
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GRAnd-4: the GeRMAn RetRoSPective AnAlySiS on PeRSiStence in woMen with oSteoPoRoSiS tReAted with BiSPhoSPhonAteS oR denoSuMAB
Hadji P 1 , Kyvernitakis J 2 , Kann P 3 , Niedhart C 4 , Hofbauer L 5 , Schwarz H 6 , Kurth AA 7 , Thomasius F 8 , Schulte M 9 , Intorcia M 10 , Psachoulia E 10 , Schmid T 9 1 Krankenhaus Nordwest, Frankfurt am Main, Germany, 2 Dpt.of Obstetrics and Gynecology, Philipps-University of Marburg, Germany, Marburg, Germany, 3 Dpt. of Gastroenterology, Endocrinology and Metabolism, Marburg, Germany, 4 Orthopedic Practice, Heinsberg, Germany, 5 University Hospital, Dresden, Germany, 6 Orthopedic Practice, reudenstadt, Germany, 7 THEMISTOCLES GLUCK Hospital GmbH, Ratingen, Germany, 8 Orthopedic Practice, Bad Homburg, Germany, 9 Amgen GmbH, Munich, Germany, 10 Amgen (Europe) GmbH, Zug, Switzerland Objectives: To be effective, osteoporosis (OP) therapy must be taken consistently and as prescribed. Persistence is critical for successful outcomes, including fracture risk reduction. Few studies compare the persistence of oral bisphosphonate (BPs), IV BPs and denosumab beyond 1 year. This retrospective database analysis evaluated 2-year persistence to oral BPs, IV BPs and denosumab following treatment initiation and the risk of treatment discontinuation. MethOds: From the German IMS®LRx database, we included women aged ≥ 45 years who initiated an OP treatment after 1-July-2010 (index date = treatment initiation) with ≥ 2 years of follow-up until 31-Dec-2014. Persistence (prescription refill gap ≤ 60 days and no drug switch) was measured for 2 years from index date, and a Cox proportional hazard regression model was used to estimate the risk of treatment discontinuation (i.e. non-persistence). Results: Data from 159,993 women were included in the analysis. Two years after treatment initiation, 39.8 % of those receiving denosumab (n= 21,154), 24.8 % receiving IV ibandronate (n= 20,472), 21.2 % receiving IV zoledronic acid (n= 3,966), and 16.7 %"Ÿ17.5 % of those receiving oral BPs were persistent. Compared with those receiving denosumab, women receiving IV ibandronate or IV zoledronic acid were at higher risk of treatment discontinuation (HR [95% CI]: 1.65 [1.61-1.69] and 1.28 [1.23-1.33] respectively; p< 0.001 for both). Moreover, women treated with oral BPs vs denosumab showed a two-fold risk of treatment discontinuation (HR [95% CI]: 2.02 [1.98-2.06] for alendronate, 2.02 [1.95-2.09] for ibandronate and 1.96 [1.91-2.01] for risedronate; p< 0.001 for all). cOnclusiOns: In our database study of women initiating BPs (oral or IV) or denosumab in routine clinical practice, 2-year persistence was highest for denosumab (1.5-2 times higher). Moreover, compared to denosumab, women treated with oral or IV BPs were at higher risk of treatment discontinuation. Such improved persistence may improve clinical outcomes, including increased fracture risk reduction.
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Self-RePoRted RheuMAtic diSeASeS And eARly RetiReMent in PoRtuGAl
Laires PA 1 , Gouveia M 2 , Canhão H 1 , Rodrigues A 3 , Gouveia N 3 , Eusébio M 3 , Branco JC 3 1 Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, Portugal, Lisbon, Portugal, 2 Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3 Sociedade Portuguesa de Reumatologia, Lisbon, Portugal Objectives: We aim to examine the association between self-reported RD and early retirement by using large real-world observational data in Portugal. MethOds: We used individual level data from the national, population-based EpiReumaPt study (September 2011 to December 2013 . 10,661 inhabitants were randomly surveyed in order to capture and characterize all cases of RD within a representative sample of the Portuguese population, which were stratified by administrative territorial units (NUTSII) . In this analysis we used all participants aged between 50 and 65 years old, near the official retirement age (N= 2,792; females: 1,727) . The association of selfreported RD and early retirement was tested using logistic regression. All estimates were computed as weighted proportions, in order to take into account the sampling design. Results: 29.9% of the Portuguese population with ages between 50 and 64 years old were officially retired. Among these, 43.2% were retired due to ill-health, which in turn about a third (30.4%) was specifically due to RD. Thus, 13.1% of all retirees self-reported RD as the main reason for early retirement. More than a third (34.2%; females: 46.3%) of all study population self-reported RD, being also more likely to self-report other main chronic disease (OR: 3.4; CI: 2.53-4.65; p< 0.001). 35.2% of RD respondents were retired versus 27.2% of those non-RD (p= 0.025). Prevalence of self-reported RD seems to be associated with early retirement (unadjusted OR: 1.45; CI: 1.05-2.01; p= 0.025). Some other characteristics are also associated with early retirement, in particular older age, male gender and presence of other chronic diseases. RD association tends to be independently associated with early retirement (adjusted OR: 1.41; CI: 1.03-1.95; p= 0.031). cOnclusiOns: These results are similar with previous data from the National Health Survey conducted in Portugal nearly a decade ago and confirms the impact that self-reported RD still have on early retirement.
PMS135 chARActeRiSticS of PAtientS StARtinG BioloGic tReAtMentS foR RheuMAtoid ARthRitiS in the ReAl woRld: SySteMAtic Review
Kilcher G, Didden E, Hummel N, Egger M University of Bern, Bern, Switzerland Objectives: To assess demographic and disease characteristics of rheumatoid arthritis (RA) patients starting treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs) in observational studies. MethOds: Systematic review of published observational studies in adult patients with RA treated with one of three biologic DMARDs (etanercept, rituximab, tocilizumab) . We identified eligible studies through electronic searches of the MEDLINE and EMBASE databases. Two reviewers screened the articles independently. We extracted study characteristics such as location and calendar period, demographics of study populations, dose, frequency and concomitant therapies, and baseline characteristics such as disease duration, the most common bone disease and its incidence is rapidly increasing with the aging population. Even if curable, it is often left untreated causing a moderate use of economic resources that could be avoided.
PMS129 Join PRoGReSS A efficiency PARtneRShiP PRoGRAM on knee Joint RePlAceMent
Espallardo O 1 , Garcia R 2 , Torner P 2 , Diaz C 2 , Colilles C 2 , Caballero F 2 , Simo I 2 , Auge A 2 , Bel X 3 , Solá M 2 , Rincon J 2 , Gomez R 2 , Lechuga F 2 , Zamora F 2 , Olivares M 2 , Garcia G 2 , Diaz C 2 , Hernando P 2 , Solá J 2 , Fernandez I 2 , Vega M 1 , Martinez V 1 1 Johnson & Johnson Medical, Madrid, Spain, 2 H. Parc Taulí, Barcelona, Spain, 3 H. Parc Taulí, Barcelonaq, Spain Objectives: Hospital Parc Taulí and Johnson & Johnson, partnered in a program to design and implant a fast track program for knee joint replacement. The objective was to decrease morbidity, functional convalesce, length of stay and increase patient and professionals satisfaction efficiently. MethOds: The implementation included 3 phases and two multidisciplinary Workgroups. Clinical aspects based on evidence, combined with organizational optimization, resources distribution and process redesign. Phase I: evaluation, nourished by Kaizen methodologies, Lean and 6 Sigma processes, Blum and Taylor laborer environment and Alex Faicknet Osborn group dynamics were taken under consideration. Phase II: Implantation, using Taylor dynamics to define the strategies to produce improvement on target indicators. Phase III: Monitoring, both from length of stay, security aspects such as morbidity, mortality, readmission rates, patient and professional satisfaction, and economic impact. Results: The length of stay is influenced by factors such as patient profile and organizational aspects. Empowered patients are more active. A new patient pathway was developed, initiated when admitted to discharge and post-operative follow up. Improvement on healthcare results, increasing patient and professional's satisfaction, and reducing 50% length of stay, resulting on significant economical savings. cOnclusiOns: Analyzing the patient pathway through an analysis methodology, reingeniery and diagnosis healthcare process (in outcomes and in direct cost), the patient involvement in the whole process can result not only in important efficiency improvement, but also improve the working environment and enhanced team work culture for a continuous process improvement.
PMS130 eStABliShinG the vAlue of eMeRGinG BioSiMilARS
Etchberger J 1 , Anwar S 1 , Smart A 2 , Venugopal A 2 , Bolger T 1 , Sasikumar D 2 , Cassese M 2 1 Navigant Consulting Inc., London, UK, 2 Navigant Consulting Inc., NY, NY, USA Objectives: The emergence of biosimilars for blockbuster therapies such as Remicade, Humira, Enbrel and Rituxan/MabThera is changing the paradigm by which traditional market access decisions are made for biologics. Furthermore, the regulatory pathway in Europe and the U.S. has raised uncertainties among clinicians regarding both the efficacy and safety of biosimilar molecules. The objectives of our research were to (1) understand the evolving mechanisms for biosimilar market access, (2) identify the key stakeholders involved in access decisions or influence and (3) determine the value drivers of biosimilars across diverse stakeholder groups. MethOds: A large sample of stakeholders (n= 271) were engaged, including clinical specialists, payers and patients, across Europe and in the U.S. We performed in-depth qualitative interviews to gain an understanding of the current landscape for biologics and expectations for biosimilars, focusing on RA, Ulcerative Colitis, Crohn's Disease and Psoriasis. Results: Our research indicates the fundamental understanding of biosimilars is inconsistent both within stakeholder groups and across different groups. Furthermore, for clinicians, a lack of accurate understanding of biosimilars can be a substantial driver of negative perception and a key barrier to anticipated adoption. Overall, each stakeholder group that will influence biosimilar market access has different value needs and expectations from biosimilars. cOnclusiOns: Our findings highlight the need for a more consistent definition of biosimilar and clinical data requirements and a tailored approach to value communication for key influencers and stakeholders in the biosimilar value chain.
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StRAteGieS -BASed on evidence-to RAtionAlize the hiGh coSt dRuGS nAtionAl liSt in the doMinicAn RePuBlic
Barillas E 1 , Valdez C 2 , Narvaez E 2 , Vasquez G 3 1 Management Sciences for Health, Arlington, VA, WA, USA, 2 Management Sciences for Health, Arlington, VA, Dominican Republic, 3 Ministry of Health, Santo Domingo, Dominican Republic Objectives: In 2014, the budget for high cost drugs in Dominican Republic (DR) was USD 107 million, accounting for 51% of the MoH budget for medicines. Resources allocated for the 2015 budget were USD 49 million, leaving a shortfall of USD 62 million. The MoH requested technical assistance from the USAID funded SIAPS project to conduct an evidence based analysis of the 98 products included in the list. MethOds: Stage 1. Gathering of Evidence and Analysis; SIAPS consultant analyzed the therapeutic benefits and cost, and proposed 4 priority levels: Priority 1: Medicines included in the WHO Essential Medicine List; Priority 2: Included in the list of a Central America and DR procurement mechanism (COMISCA); Priority 3: Not included in the preceding groups but with scientific evidence of therapeutic benefits and approved by EMA and FDA; Priority 0: Medicines for which evidence on benefits was insufficient or for which better/cheaper alternatives were available. Stage 2. Review and approval by national scientific committee. During a two-day workshop, clinical specialists reviewed the proposed priority groups, consulted literature and proposed modifications supported by scientific evidence. Results: In the plenary session, the scientific committee, agreed by consensus on the final version of the high cost drugs list to be procured in 2015. Of the 98 medicines, 22 were on the WHO list and 17 were on the COMISCA; 14 of the remaining 59 medicines were also included because there was scientific evidence of its benefits. Total of 45 medicines were removed by consensus, with a budget decrease of 53 % and savings of USD 21 million. cOnclusiOns: A review -based on evidence-followed by a consensus reached with clinical specialists allowed to select the number of products to be
